Healthcare News

KØBENHAVN, Danmark, 21. august 2026 – Bavarian Nordic A/S (OMX: BAVA) offentliggjorde i dag sine delårsresultater og den forretningsmæssige udvikling for andet kvartal og første halvår af 2026 samt...

Repurchased shares will be subject to cancellation, pending shareholder resolution COPENHAGEN, Denmark, August 21, 2026 – Bavarian Nordic A/S (OMX: BAVA) today announced its plans to launch a new...

De tilbagekøbte aktier vil blive annulleret, forudsat godkendelse fra aktionærerne KØBENHAVN, Danmark, 21. august 2026 – Bavarian Nordic A/S (OMX: BAVA) offentliggjorde i dag hensigt om at lancere et...

Guidance upgrade reflects upper end of previous guided revenue range and an improved EBITDA margin COPENHAGEN, Denmark, August 21, 2026 – Bavarian Nordic A/S (OMX: BAVA) today announced an upgrade of...

Opjusteringen afspejler den øvre ende af det tidligere udmeldte omsætningsinterval samt en forbedret EBITDA-margin KØBENHAVN, Danmark, 21. august 2026 – Bavarian Nordic A/S (OMX: BAVA) meddelte i...

PARIS, FRANCE, 21 AUGUST 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today it has completed the acquisition of Kartos Therapeutics, a clinical-stage biopharmaceutical company adding late-stage...

PARIS, FRANCE, 21 AOUT 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) a annoncé aujourd’hui avoir finalisé l'acquisition de Kartos Therapeutics, une société biopharmaceutique au stade clinique, apportant le...

Rock Hill, SC, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Keystone, a long-standing provider of substance misuse prevention, intervention, treatment and recovery services in the region, today announced it...

TORONTO, and HAIFA, Israel, Aug. 21, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing...

MISSISSAUGA, Ontario, Aug. 20, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its Board of Directors has declared a quarterly...